DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Total Liabilities
Everything the company owes to creditors and other parties.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 19.9% from a year ago
Total liabilities stood at $5.85M at the end of Q1 FY2026, up 19.9% from a year earlier and up 11.1% from the prior quarter. Over 3 fiscal years it compounded at +27.0% a year.
Context
- Total liabilities amounted to 11.0% of total assets at the end of Q1 FY2026, down 1.5 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +19.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 5.26M USD
- Year-over-year change
- -6.5%
- 4-year CAGR
- +36.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.26M | -6.5% |
| FY2024 | 2024-12-31 | 5.63M | +81.3% |
| FY2023 | 2023-12-31 | 3.1M | +20.8% |
| FY2022 | 2022-12-31 | 2.57M | +68.2% |
| FY2021 | 2021-12-31 | 1.53M | — |
Total Liabilities vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's Mar 2026 total liabilities of $5.85M is the lowest of the 7 companies compared; the peer median is $53.84M.
- Its year-over-year change of +19.9% is the 4th highest of 7, against a peer median of +38.7%.
- Total liabilities amounts to 11.0% of total assets for DMAC, versus a peer median of 23.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $335.15M | +17.3% | -0.7% | 92.4% | |
| Jun 2026 | $322.78M | +131.9% | -32.0% | 27.9% | |
| Mar 2026 | $78.01M | +91.3% | -4.6% | 18.6% | |
| Mar 2026 | $29.68M | -17.7% | +38.6% | 10.1% | |
| Mar 2026 | $26.7M | +60.1% | +79.3% | 41.5% | |
BIOABioAge Labs, Inc. | Mar 2026 | $18.53M | -39.6% | -45.5% | 4.7% |
| Mar 2026 | $5.85M | +19.9% | +27.0% | 11.0% | |
| Peer median (excluding DMAC) | $53.84M | +38.7% | -2.6% | 23.2% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.